Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document

Abstract Objective To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis. Methods Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi procedure were carried out. A steering committee from the Spanish Group of Psoriasis was established who based on the reviews generated a set of related statements. Subsequently, a group of 40 experts tested their agreement with the statements, through 3 Delphi rounds. Results We found a great variability in clinical guidelines regarding to the definition of treatment goal and the response. In general, treatment failure was considered if a PASI50 is not achieved. The panel of experts agreed on (1) clearly differentiate between ideal and a realistic goals when establishing the therapeutic goal in moderate to severe psoriasis; (2) treatment goals should be in general established regardless of the type of drug for psoriasis; (3) treatment failure if PASI75 response is not reached; (4) an absolute PASI is in general preferred to the rate of PASI improvement from baseline; (5) disease characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals. Conclusions A clear treatment decision making framework is vital to improve management of psoriasis. KEY MESSAGES Psoriasis characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals. Different disease indexes could be used to assess treatment response but absolute PASI is preferred In general psoriasis treatment failure should be considered if PASI75 response is not reached

[1]  T. Dilla,et al.  Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature , 2020, PloS one.

[2]  G. Pellacani,et al.  A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  A. Armstrong,et al.  Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. , 2020, JAMA dermatology.

[4]  D. Shrom,et al.  Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey , 2019, Dermatology and Therapy.

[5]  Jacqueline Pich Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. , 2019, International journal of evidence-based healthcare.

[6]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. , 2019, Journal of the American Academy of Dermatology.

[7]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[8]  M. Tauber,et al.  French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  L. Naldi,et al.  A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey , 2018, The British journal of dermatology.

[10]  A. Florek,et al.  Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review , 2018, Archives of Dermatological Research.

[11]  P. Gisondi,et al.  European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  L. Coates,et al.  British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 , 2017, The British journal of dermatology.

[13]  L. Cordingley,et al.  ‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed‐methods feasibility study , 2017, The British journal of dermatology.

[14]  L. Naldi,et al.  Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  I. Belinchón,et al.  Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature , 2016, Patient preference and adherence.

[16]  L. Puig,et al.  Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  A. Nast,et al.  Methods Report: European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  P. Gisondi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  L. Cordingley,et al.  Patient‐reported outcome measures in psoriasis: the good, the bad and the missing! , 2015, The British journal of dermatology.

[20]  R. Ruiz-Villaverde,et al.  Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas) , 2014 .

[21]  J. M. Carrascosa,et al.  Prevalence of psoriasis in Spain in the age of biologics. , 2014, Actas dermo-sifiliograficas.

[22]  S. Marron,et al.  Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.

[23]  J. M. Carrascosa,et al.  Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I . Consideraciones de eficacia y selección del tratamiento , 2013 .

[24]  S. Shumack,et al.  Treatment goals for moderate to severe psoriasis: An Australian consensus , 2013, The Australasian journal of dermatology.

[25]  J. Cappelleri,et al.  Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses , 2012, Dermatology and Therapy.

[26]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[27]  A. Nast,et al.  Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  C. F. Foraster,et al.  Impacto de la psoriasis en la calidad de vida relacionada con la salud , 2007 .

[29]  S. Puig,et al.  Prevalence of psoriasis in Spain (Epiderma Project: phase I) , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  Robert J G Chalmers,et al.  Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. , 2015, Dermatologic clinics.

[31]  A. García‐Díez,et al.  [Impact of psoriasis on health-related quality of life]. , 2007, Medicina clinica.

[32]  H. Williams,et al.  A systematic review of treatments for severe psoriasis. , 2000, Health technology assessment.